Athersys inc.®

Building a Better Future

ESG Presentation

Corporate ESG Performance

Prime

RATED BY ISS ESG

Building a Better Future Through Our Mission

We are committed to addressing areas of significant unmet medical need through the development of innovative regenerative medicine therapies that extend and enhance the quality of human life.

Athersys inc. ®

Without our health, we have nothing

It is hard to argue against health being the most important of all environmental, social and governance (ESG) values. So we start by asking, what are some of the biggest threats to global health?

Stroke

Current treatments are largely ineffective unless administered within a few hours of the stroke—too late for most victims.

17M

people suffer a stroke every year

Acute Respiratory Distress Syndrome (ARDS)

ARDS is the leading cause of death among COVID-19 patients. ARDS treatments require extended and expensive hospital care, and patients frequently experience quality of life issues in the aftermath.

~500,000

people afflicted annually (in a non-pandemic year)

Trauma

Trauma is the leading cause of death and serious disability among Americans age <45. It is also the leading cause of life years lost before age 75 and a major source of disability for youth, the elderly and military personnel.

180,000

fatalities per year in the U.S.

Our MultiStem® cell therapy holds promise for each of these and more

This promise is real and near term. MultiStem is a patented regenerative medicine that has shown promise promoting tissue repair and healing in a variety of ways.

MultiStem is being evaluated in several clinical-stage programs, including ischemic stroke, ARDS and trauma (two of which are pivotal Phase 3 trials). This technology has received Fast Track and RMAT designations from the FDA (as well as similar designations in Europe and Japan). We are actively developing the manufacturing process for MultiStem in large scale bioreactors and gearing up for potential approval.

And this potential is free of many of the challenges other stem cell treatments have:

- No fetal or embryonic stem cells used; only bone marrow from healthy consenting adults
- Favorable and consistent tolerability data
- Highly scalable
- Easy to transport, store, and administer

And this is only the beginning. We have over 300 patents related to these technologies and are working with leading clinical experts, hospitals and research institutions, as well as other partners to develop MultiStem for additional indications.



Based on Proprietary MAPC Technology

Broad IP estate covering core technology, methods of production & areas of use



Promotes Healing and Tissue Repair

Works through multiple mechanisms of action

Administered Systemically or Locally

Off the shelf administration with no tissue matching or immune suppression required

Long Shelf Life

Consistent safety & tolerability profile, with > 8 years of stability data on cryogenically stored product

Advancing our robust pipeline towards commercialization

We have established a diverse portfolio of diseases and conditions for treatment in regenerative medicine, with an emphasis on treating critical care indications.



Our ability to help people (the S in ESG) extends beyond working to treat some of the most feared, most lethal, most expensive, and most widespread of medical conditions

We have a diverse global workforce and are led by a Board, 56% of whom (5 of 9) are diverse by race, ethnicity or gender, and a management team with similar diversity. 59% of our global workforce are women, with 59% of our management positions held by women.

We also employ a variety of positions, including full-time workers, part-time workers, temporary workers, contract workers, and interns.

Our people are our brain trust.

We work to enhance their well-being and creativity, and demonstrate our commitment via numerous health, wellness, retirement and other benefit programs, growth and development opportunities, community outreach programs and active listening and feedback loops.

Working in a cutting-edge medical field helps us attract top talent. We believe in the quality of our Company's therapies, our strong corporate culture and our unified mission to help patients and their families.

We have few environmental risks but take numerous opportunities to show environmental leadership

We run environmentally responsible laboratory waste collection, recycling and disposal programs.

We are ramping up our manufacturing and facilities capabilities using leading environmentally responsible and carbon footprint principles.

We encourage our employees to be environmental leaders. We have a strong and longstanding commitment to volunteering, philanthropic activities, employee wellness and education.

We have a strong governance structure that supports our leading scientific and development profile

Our governance profile is unusually advanced for a pre-commercial biotech of our size:

- One class of voting shares (no dual class cap)
- Annual director elections (no staggered board)
- No super majority provisions or poison pill
- Majority voting
- Special meeting and written consent rights
- Board and management team diverse by gender, race, ethnicity and national origin
- Active Board refreshment process; five new non-management directors since 2018
- Annual Board and key committee self-assessment review
- Exemplary internal and external pay parity
- Robust ethics and conflicts policies



A strong governance structure without strong leaders at the Board and management level is not enough. We have both.

Name	Title	Prior Experience
 William (B.J.) Lehmann, JD	Interim CEO, President & COO	McKinsey&Company, Stanford Law School, Chicago Booth School of Business, WSGR
 John Harrington, PhD	EVP and CSO, Board member	AMGEN, Scripps, Stanford Medicine
 Ivor Macleod, MBA, CPA	CFO	Eisai, MERCK, Roche, mannheim boehringer
 Manal Morsy, MD, PhD	SVP, Global Regulatory Affairs	EVMS Eastern Virginia Medical School, MERCK, Johnson & Johnson, PTC Therapeutics
 Maia Hansen, MBA, MS	SVP, Operations and Supply Chain	McKinsey&Company, MIT Management Sloan School
 James Glover, BS, PMP	SVP, Commercial Manufacturing	emergent biosolutions, Pii Pharmaceutics International, Inc, DYNAVAX, Bayer, Novartis

Our Board of Directors

Name	Title	Professional Affiliations*	Educational & Policy Affiliations*
 Ismail Kola, PhD	Chairman *(Since February 2021; director since October 2010)*	Pharmacia, Promega, Merck, Ondek, Schering-Plough Research Institute, UCB, astex pharmaceuticals, Schering-Plough	Pembroke College Cambridge, Monash University, University of Cape Town, Rhodes University, Nuffield College, Washington University in St. Louis, Karolinska Institutet
 John Harrington, PhD	Director *(Since founding in 1995)*	Amgen, Scripps	University of California San Diego, Stanford School of Medicine
 Hardy TS Kagimoto, MD	Director *(Since June 2018)*	Aqumen, Healios	九州大学 Kyushu University
 Katherine Kalin, MBA	Independent Director *(Since November 2020)*	Johnson & Johnson, Genfit, Stardog, Brown Advisory, Primari Analytics, Celgene, McKinsey & Company	Harvard Business School, Durham University
 Lorin J. Randall, MBA	Independent Director *(Since September 2007)*	Opexa Therapeutics, tengion, Acorda Therapeutics, i-STAT, Nanosphere, Eximias, CFM Technologies	Northeastern University, PennState
 Baiju R. Shah, JD	Independent Director *(Since November 2020)*	Citizens Financial Group, Inc., Invacare, BioEnterprise, Cleveland Foundation, FasterCures, BioMotiv, McKinsey & Company	Harvard Law School, Yale
 Kenneth H. Traub	Director *(Since February 2021)*	DSP Group, Intermolecular, immersion, voxware, Tidewater, Ethos Management	Emory University, Harvard Business School
 Jane Wasman, JD	Independent Director *(Since November 2020)*	NewYorkBIO, Cytovia Therapeutics, Acorda Therapeutics, Ellas, rigel, Schering-Plough	Princeton University, Harvard Law School
 Jack L. Wyszomierski, MS	Independent Director *(Since June 2010)*	SiteOne Landscape Supply, JOY, Exelixis, vwr, XOMA, Solenis, Schering-Plough	Carnegie Mellon University

* includes current and previous affiliations

Thank You